Acquired Resistance to EGFR-TKI in the Uncommon EGFR Mutation, G719S

被引：0
|
作者：
Osoegawa, A. [1 ]
Hashimoto, T. [1 ]
Takumi, Y. [1 ]
Kobayashi, R. [1 ]
Miyawaki, M. [1 ]
Takeuchi, H. [1 ]
Okamoto, T. [1 ]
Sugio, K. [1 ]
机构：
[1] Oita Univ, Fac Med, Dept Thorac & Breast Surg, Yufu, Japan
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 11期
关键词：
Acquired resistance; EGFR-TKI; PTEN;
D O I：
10.1016/j.jtho.2017.09.1568
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3.02-039
引用
收藏
页码：S2251 / S2251
页数：1
相关论文
共 50 条
  • [41] Bevacizumab to combat EGFR-TKI resistance in a patient with advanced non-small cell lung cancer harboring an EGFR mutation: A case report
    Wang, Zhiyi
    Zhou, Pu
    Li, Guanghui
    ONCOLOGY LETTERS, 2016, 12 (01) : 356 - 360
  • [42] Comparison of EGFR-TKI and chemotherapy in the first-line treatment of advanced EGFR mutation-positive NSCLC
    Fiala, O.
    Pesek, M.
    Finek, J.
    Benesova, L.
    Bortlicek, Z.
    Minarik, M.
    NEOPLASMA, 2013, 60 (04) : 425 - 431
  • [43] EGFR inhibitor and chemotherapy combinations for acquired TKI resistance in EGFR-mutant NSCLC models
    Niina Laurila
    Jussi P. Koivunen
    Medical Oncology, 2015, 32
  • [44] EGFR inhibitor and chemotherapy combinations for acquired TKI resistance in EGFR-mutant NSCLC models
    Laurila, Niina
    Koivunen, Jussi P.
    MEDICAL ONCOLOGY, 2015, 32 (07)
  • [45] A Comparison of ddPCR and ARMS for detecting EGFR T790M status in ctDNA from advanced NSCLC patients with acquired EGFR-TKI resistance
    Wang, Wenxian
    Song, Zhengbo
    Zhang, Yiping
    CANCER MEDICINE, 2017, 6 (01): : 154 - 162
  • [46] Co-administration of 20(S)-protopanaxatriol (g-PPT) and EGFR-TKI overcomes EGFR-TKI resistance by decreasing SCD1 induced lipid accumulation in non-small cell lung cancer
    Huang, Quanfu
    Wang, Qiuguo
    Li, Dong
    Wei, Xiao
    Jia, Yijuan
    Zhang, Zheng
    Ai, Bo
    Cao, Xiaonian
    Guo, Tao
    Liao, Yongde
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2019, 38 (1)
  • [47] Molecular mechanism of acquired drug resistance in the EGFR-TKI resistant cell line HCC827-TR
    Yu, Tao
    Xia, Qian
    Gong, Ting
    Wang, Jing
    Zhong, DianSheng
    THORACIC CANCER, 2020, 11 (05) : 1129 - 1138
  • [48] Efficacy and safety of original EGFR-TKI combined with bevacizumab in advanced lung adenocarcinoma patients harboring EGFR-mutation experiencing gradual progression after EGFR-TKI treatment: a single-arm study
    Long, Jianlin
    Lei, Shuangyi
    Wu, Zhijuan
    Xiong, Shuanglong
    Wang, Chunmei
    Huang, Lumi
    Liang, Guanzhong
    Yang, Dan
    Teng, Yan
    Li, Yongsheng
    Qi, Jun
    Li, Dairong
    ANNALS OF TRANSLATIONAL MEDICINE, 2022, 10 (24)
  • [49] Acquired EGFR T790M Mutation After Relapse Following EGFR-TKI Therapy: A Population-based Multi-institutional Study
    Kaburagi, Takayuki
    Kiyoshima, Moriyuki
    Nawa, Takeshi
    Ichimura, Hideo
    Saito, Takefumi
    Hayashihara, Kenji
    Yamada, Hideyasu
    Satoh, Hiroaki
    Endo, Takeo
    Inage, Yoshihisa
    Saito, Kazuhito
    Inagaki, Masaharu
    Hizawa, Nobuyuki
    Sato, Yukio
    Ishikawa, Hiroichi
    Sakai, Mitsuaki
    Kamiyama, Koichi
    Kikuchi, Norihiro
    Nakamura, Hiroyuki
    Furukawa, Kinya
    Kodama, Takahide
    Yamashita, Takaaki
    Nomura, Akihiro
    Yoshida, Susumu
    ANTICANCER RESEARCH, 2018, 38 (05) : 3145 - 3150
  • [50] Exon 19 L747P mutation presented as a primary resistance to EGFR-TKI: a case report
    Wang, Yu-Ting
    Ning, Wei-Wei
    Li, Jing
    Huang, Jian-An
    JOURNAL OF THORACIC DISEASE, 2016, 8 (07) : E542 - E546
12345